---
format: 
  revealjs:
    hash-type: number
    transition: fade
    auto-stretch: false
    self-contained: true
    height: 900
    width: 1600
    footer: ""
    slide-number: c/t
    css: "font.css"
knitr: 
  opts_chunk: 
    echo: false
editor_options: 
  chunk_output_type: console
---

##  {}

::: {style="position: absolute; left: 180px; top: 200px; height: 525px; width: 1200px; background-color: #ffffff; padding: 20px; padding-left: 50px; box-shadow: 0px 15px 0px 0px #6C3483; border-radius: 5px;"}
[Leveraging real-world data and randomised controlled trials to advance personalised medicine]{style="font-size: 70px; font-weight: bold; line-height: 1em; margin: 0px"}

<br>

[Ignacio Leiva-Escobar]{style="font-size: 50px; font-weight: bold; color: #808080"} <br> 
[MSc Epidemiology - Charité Universitätsmedizin Berlin]{style="font-size: 25px;color: #808080"}  <br> 
[MSc Health Data Science - LSHTM]{style="font-size: 25px;color: #808080"} 

[2023]{style="font-size: 50px;font-weight: bold;"}
:::



## [Randomised Controlled Trials]{style="font-size: 70px; font-weight: bold; line-height: 1em; margin: 0px; color: #6C3483"}

\

- `RCT III` are Gold Standard for Drug approval (Efficacy) 
- Designed to generate internally valid treatment effect


  - Randomization/Masking
  

  - Monitoring and follow-up
- Included in clinical guidelines 
- Used by Health care providers



## [Target population]{style="font-size: 70px; font-weight: bold; line-height: 1em; margin: 0px; color: #581845"}

::: {.r-hstack}


::: {data-id="box1" auto-animate-delay="0" style="background-image: url('foto.png'); background-size: cover; background-position: contain; width: 650px; height: 500px; margin: 50px;"}
:::

::: {data-id="box2" auto-animate-delay="0.1"  style="background: #ffff ; width: 350px; height: 300px ; margin: 10px;"}
:::
:::


## [Trial population]{style="font-size: 70px; font-weight: bold; line-height: 1em; margin: 0px; color: #581845"}


::: {.r-hstack}

::: {data-id="box1" auto-animate-delay="0" style="background-image: url('foto.png'); background-size: cover; background-position: contain; width: 650px; height: 500px; margin: 50px;"}
:::

::: {data-id="box2" auto-animate-delay="0.1" style="background-image: url('foto2.png'); background-size: cover; background-position: contain; width: 350px; height: 300px ; margin: 10px;"}
:::

:::


::: {style="position: absolute; left: 940px; top: 300px; height: 10px; width: 100px; border:0px solid #fffff ;background-color: #ffffff; padding: 5px; box-shadow: 0px 0px 0px 0px #6C3483; border-radius: 5px;"}
[&rarr;]{style="font-size: 60px;"}
:::


## [Trial population]{style="font-size: 70px; font-weight: bold; line-height: 1em; margin: 0px; color: #581845"}

::: {style="position: absolute; left: 740px; top: 0px; height: 300px; width: 800px; border:0.2px solid #6C3483 ;background-color: #ffffff; padding: 15px; box-shadow: 0px 0px 0px 0px #6C3483; border-radius: 5px;"}
::: {.r-hstack}

::: {data-id="box1" auto-animate-delay="0" style="background-image: url('foto.png'); background-size: cover; background-position: contain; width: 350px; height: 250px; margin: 50px;"}
:::

::: {data-id="box2" auto-animate-delay="0.1" style="background-image: url('foto2.png'); background-size: cover; background-position: contain; width: 240px; height: 190px ; margin: 10px;"}
:::

:::


::: {style="position: absolute; left: 450px; top: 100px; height: 10px; width: 100px; border:0.2px solid #fffff ;background-color: #ffffff; padding: 15px; padding-left: 20px; box-shadow: 0px 0px 0px 0px #6C3483; border-radius: 5px;"}
[&rarr;]{style="font-size: 70px;"}
:::

:::

<br><br><br><br><br><br><br><br>

. . .

::: {.custom-callout}

[Random sample | ]{style="font-size: 35px; font-weight: bold;color: #000000"}
[ $ATE_{trial\ population} = ATE_{target\ population}$]{style="font-size: 25px; font-weight: bold; color: #000000"}

:::

\ 

. . .

::: {.custom-callout}

[No random sample | ]{style="font-size: 35px; font-weight: bold;color: #000000"}
[ $ATE_{trial\ population} \neq ATE_{target\ population}$]{style="font-size: 25px; font-weight: bold; color: #000000"}

> [Distribution EM: Age, Sex, Renal Function]{style="font-size: 20px; color: #4a235a"}

:::








## [External &  Internal validity ^[Raymond S. Greenberg, Medical Epidemiology, Third Edition]]{style="font-size: 67px; font-weight: bold; line-height: 1em; margin: 0px; color: #6C3483"}


::: {style="position: absolute; left: 30px; top: 200px; height: 370px; width: 600px; border:0.2px solid #D9D9D9 ;background-color: #ffffff; padding: 15px; padding-left: 20px; box-shadow: -7px 0px 0px 0px #85929e; border-radius: 5px;"}

[Internal Validity]{style="font-size: 35px; font-weight: bold;color: #000000"}

\

[“The extent to which the results of an investigation accurately reflect the situation of the study  population”]{style="font-size: 35px; font-weight: bold; color: #797474"}
:::




::: {style="position: absolute; left: 800px; top: 200px; height: 370px; width: 600px; border:0.2px solid #D9D9D9 ;background-color: #ffffff; padding: 15px; padding-left: 20px; box-shadow: -7px 0px 0px 0px #c39bd3; border-radius: 5px;"}

[External Validity]{style="font-size: 35px; font-weight: bold;color: #000000"}

\ 

[“The extent to which the results of a study are applicable to other populations”]{style="font-size: 35px; font-weight: bold; color: #797474"}

:::

## External validity can be divided into ^[Dahabreh IJ, Robertson SE, Steingrimsson JA, Stuart EA, Hernan MA. Extending inferences from a randomized trial to a new target population. Stat Med. 2020;39(14):1999-2014.]  {auto-animate=true auto-animate-easing="ease-in-out"}

::: {style="position: absolute; left: 180px; top: 200px; height: 370px; width: 600px; border:0px solid #D9D9D9 ;background-color: #ffffff; padding: 0px; padding-right: 0px; box-shadow: 0px 0px 0px 0px #c39bd3; border-radius: 5px;"}



::: {.r-hstack}
::: {data-id="box1" auto-animate-delay="0" style="background: #c39bd3; width: 200px; height: 150px; margin: 10px;"}

[Target A]{style="font-size: 35px; font-weight: bold; color: #ffffff; padding-left: 35px;"}

:::

::: {data-id="box2" auto-animate-delay="0.1" style="background: #344c5c; width: 100px; height: 150px ;margin-right:-280px; "}
:::



:::
:::

::: {style="position: absolute; left: 710px; top: 200px; height: 370px; width: 600px; border:0px solid #D9D9D9 ;background-color: #ffffff; padding: 0px; padding-left: 0px; box-shadow: 0px 0px 0px 0px #c39bd3; border-radius: 5px; "}


::: {.r-hstack}

::: {data-id="box2" auto-animate-delay="0.1" style="background: #344c5c; width: 100px; height: 150px; margin-left:-280px;"}

 [Trial]{style="font-size: 35px; font-weight: bold; color: #ffffff; padding-left: 5px;"}

:::

::: {data-id="box1" auto-animate-delay="0" style="background: #85929e; width: 200px; height: 150px; margin: 10px;"}

[Target B]{style="font-size: 35px; font-weight: bold; color: #ffffff; padding-left: 35px;"}

:::


:::
:::




## External validity can be divided into {auto-animate=true auto-animate-easing="ease-in-out"}
::: {style="position: absolute; left: 200px; top: 200px; height: 370px; width: 600px; border:0px solid #D9D9D9 ;background-color: #ffffff; padding: 15px; padding-right: 0px; box-shadow: 0px 0px 0px 0px #c39bd3; border-radius: 5px; margin: 0px; float: left"}

[Generalisability]{style="font-size: 35px; font-weight: bold;color: #000000; text-align: center;padding-left: 130px;"}

\

::: {.r-stack}
::: {data-id="box1" style="background: #c39bd3; width: 350px; height: 350px; border-radius: 200px;"}
[Target A]{style="font-size: 35px; font-weight: bold; color: #ffffff; padding-left: 110px;"}
:::

::: {data-id="box2" style="background: #344c5c; width: 150px; height: 150px; border-radius: 100px;"}
[Trial]{style="font-size: 35px; font-weight: bold; color: #ffffff; padding-left: 40px;"}
:::

:::
:::
::: {style="position: absolute; left: 800px; top: 200px; height: 370px; width: 600px; border:0px solid #D9D9D9 ;background-color: #ffffff; padding: 15px; padding-left: 20px; box-shadow: 0px 0px 0px 0px #c39bd3; border-radius: 5px;"}

[Transportability]{style="font-size: 35px; font-weight: bold;color: #000000; text-align: center;padding-left: 110px;"}


\

::: {.r-hstack}
::: {data-id="box1" style="background: #85929e; width: 350px; height: 350px; border-radius: 200px;"}
[Target B]{style="font-size: 35px; font-weight: bold; color: #ffffff; padding-left: 110px;"}
:::

::: {data-id="box2" style="background: #344c5c; width: 150px; height: 150px; border-radius: 200px;left: 1200px;"}
[Trial]{style="font-size: 35px; font-weight: bold; color: #ffffff;padding-left: 40px;"}
:::


:::
:::


## How can we address External validity {auto-animate=true}

\

> [Trial design approaches]{style="font-size: 50px; font-weight: bold; line-height: 1em; margin: 0px; color: #6C3483"} 

  - Doubly randomized trials
  - Pragmatic trials
\ 

. . .

> [Analytic approaches]{style="font-size: 50px; font-weight: bold; line-height: 1em; margin: 0px; color: #6C3483"} 

  - Observational analyses / target trial emulation
  - Generalisability/transportability using trial and observational data
  
## {background-color="#471337"}


<p style="margin:650px;"></p>

[Generalisability/transportability analyses]{style="font-size: 70px; font-weight: bold; line-height: 1em; margin: 0px; color: #ffffff"}


[Remark |  In this talk, we will treat transportability and generalisability as the same problem: extending inferences from trials to target populations of interest]{style="font-size: 30px"}


## [Check the]{style="font-size: 67px; font-weight: light; line-height: 1em; margin: 0px; color: #6C3483 "} Identifiability conditions ^[Degtiar I, Rose S. A Review of Generalizability and Transportability. Annual Review of Statistics and Its Application. 2023;10(1):501-24]

::: {style="position: absolute; left: 330px; top: 150px; height: 250px; width: 1100px; background-color: #ffffff; padding: 20px; padding-left: 50px; box-shadow: 0px 0px 7px 0px #4a235a; border-radius: 5px; border:0.2px solid #D9D9D9"}

[(I) Consistency of potential outcomes]{style="font-size: 30px; font-weight: bold; line-height: 1em; margin: 0px; color: #4a235a"}

[(II) Mean exchangeability in the trial]{style="font-size: 30px; font-weight: bold; line-height: 1em; margin: 0px; color: #4a235a"}

[(III) Positivity of treatment assignment]{style="font-size: 30px; font-weight: bold; line-height: 1em; margin: 0px; color: #4a235a"}
:::

::: {style="position: absolute; left: 20px; top: 150px; height: 250px; width: 230px; background-color: #4a235a; padding: 20px; padding-left: 50px; box-shadow: 0px 0px 7px 0px #4a235a; border-radius: 5px; border:0.2px solid #D9D9D9"}

\

[RCT]{style="font-size: 50px; font-weight: bold; line-height: 1em; margin: 0px; color: #ffffff"} 

[Internal Validity]{style="font-size: 30px; font-weight: bold; line-height: 1em; margin: 0px; color: #ffffff"} 

:::

. . .

::: {style="position: absolute; left: 330px; top: 500px; height: 250px; width: 1100px; background-color: #ffffff; padding: 20px; padding-left: 50px; box-shadow: 0px 0px 7px 0px #fab724; border-radius: 5px; border:0.2px solid #D9D9D9"}
[(IV) Conditional exchangeability for study selection* ]{style="font-size: 30px; font-weight: bold; line-height: 1em; margin: 0px; color: #D69E02"}

[(V) Positivity of trial participation*]{style="font-size: 30px; font-weight: bold; line-height: 1em; margin: 0px; color: #D69E02"}

[Additionally:]{style="font-size: 30px; font-weight: bold; line-height: 1em; margin: 0px; color: #D69E02"}
[(1) There are no unmeasured variables associated with treatment effect and trial sample selection 
(2) Well-specify model]{style="font-size: 25px; font-weight: bold; line-height: 1em; margin: 0px; color: #D69E02"}



:::


::: {style="position: absolute; left: 20px; top: 500px; height: 250px; width: 230px; background-color: #fab724; padding: 20px; padding-left: 50px; box-shadow: 0px 0px 7px 0px #fab724; border-radius: 5px; border:0.2px solid #D9D9D9"}

\

[Extend RCT]{style="font-size: 40px; font-weight: bold; line-height: 1em; margin: 0px; color: #ffffff"} 

[External Validity]{style="font-size: 30px; font-weight: bold; line-height: 1em; margin: 0px; color: #ffffff"} 

:::

## {background-color="#471337"}


<p style="margin:650px;"></p>

[Populations' data]{style="font-size: 70px; font-weight: bold; line-height: 1em; margin: 0px; color: #ffffff"}


## Require patient-data level^[Dahabreh IJ, Robertson SE, Steingrimsson JA, Stuart EA, Hernan MA. Extending inferences from a randomized trial to a new target population. Stat Med. 2020;39(14):1999-2014.]

\ 
 
> [Trial population:]{style="font-size: 50px; font-weight: bold; line-height: 1em; margin: 0px; color: #6C3483"}  covariates, exposure, outcome

\

> [Target population:]{style="font-size: 50px; font-weight: bold; line-height: 1em; margin: 0px; color: #6C3483"}  covariates, outcome*

\ 

Include as many potential [effect modifiers]{style="font-size: 45px; font-weight: bold; line-height: 1em; margin: 0px; color: #6C3483"} as possible

   - Matter-knowledge 
   - Subgroups analysis 
   - Previous evidence


## {}
 \
 
::: {.callout-warning title="Example"}
## Limitations

Data availability of target population

__Keep in mind:__
 
 - Information on variables (especially EM)
 
 - Differences in the ascertainment of variables (compared to RCT)
:::

<br><br>

::: {.callout-tip title="Example"}
## What look for
 - Patients need to fulfil inclusion/exclusion criteria*

 - Have measurements of relevant effect modifiers identified
:::

## {background-color="#471337"}


<p style="margin:650px;"></p>

[Type of analyses]{style="font-size: 70px; font-weight: bold; line-height: 1em; margin: 0px; color: #ffffff"}

## Estimation of _average treatment effect_ in the target population ^[Dahabreh IJ, Robertson SE, Tchetgen EJ, Stuart EA, Hernán MA. Generalizing causal inferences from individuals in randomized trials to all trial-eligible individuals. Biometrics. 2019;75(2):685-94]

\

> [Inverse probability (IP) weighting]{style="font-size: 50px; font-weight: bold; line-height: 1em; margin: 0px; color: #6C3483"} estimators that rely on modelling the probability of  participation in the trial
\

. . .

> [Outcome model-based]{style="font-size: 50px; font-weight: bold; line-height: 1em; margin: 0px; color: #6C3483"} estimators that rely on modelling the expectation of the outcome
\ 

. . .

> [Augmented IP weighting]{style="font-size: 50px; font-weight: bold; line-height: 1em; margin: 0px; color: #6C3483"} estimators that rely on modelling both the expectation of the outcome and the probability of participation in the trial. 

## {background-color="#471337"}


<p style="margin:700px;"></p>

[Inverse probability weighting estimators]{style="font-size: 70px; font-weight: bold; line-height: 1em; margin: 0px; color: #ffffff"}

## Inverse probability weighting estimators

::: {style="position: absolute; left: 20px; top: 200px; height: 380px; width: 420px; background-color: #ffffff; padding: 20px; padding-left: 50px; box-shadow: 0px 0px 10px 0px #fab724; border-radius: 5px; border:0.2px solid #D9D9D9"}
IPW estimators model the [probability of participation in the trial]{style="font-size: 40px; font-weight: bold; line-height: 1em; margin: 0px; color: #D69E02"}  (sampling) using participant characteristics, similar to the propensity score 
:::

::: {style="position: absolute; left: 560px; top: 200px; height: 380px; width: 420px; background-color: #ffffff; padding: 20px; padding-left: 50px; box-shadow: 0px 0px 10px 0px #fb92a4; border-radius: 5px; border:0.2px solid #D9D9D9"}
Trial  population is used to create a [new target population]{style="font-size: 40px; font-weight: bold; line-height: 1em; margin: 0px; color: #B84C65"} (re-weighted trial participants) with the same distribution of the target population
:::

::: {style="position: absolute; left: 1100px; top: 200px; height: 380px; width: 420px; background-color: #ffffff; padding: 20px; padding-left: 50px; box-shadow: 0px 0px 7px 0px #4a235a; border-radius: 5px; border:0.2px solid #D9D9D9"}
It can be done using Logistic regression or machine learning methods. 
Use the [outcome]{style="font-size: 40px; font-weight: bold; line-height: 1em; margin: 0px; color: #9B4EBB"} of the weighted trial population in the analysis.
:::




## It looks like

<br>

```{mermaid}
%%| fig-width: 15
%%{init: {'themeVariables': { 'primaryColor': '#ff0000',"fontSize": "10px"}}}%%
        graph LR
          A["Target Population #32;"] -->|"Covariates #32;"| C["Model #32;"]
          B["Trial Population #32;"] -->|"Covariates <br> outcome <br> treatment #32;" <br>.| C["Model #32;"]
          C --> D["Re-weighted <br> trial population #32;" <br>.]
          

```





## {background-color="#471337"}


<p style="margin:700px;"></p>

[Outcome-model based estimators]{style="font-size: 70px; font-weight: bold; line-height: 1em; margin: 0px; color: #ffffff"}

## [Outcome-model based estimators]{style="font-size: 67px; font-weight: bold; line-height: 1em; margin: 0px; color: #6C3483"}

\

 - Use trial data to build a prediction model.
 - Recommended building one model for [each arm]{style="font-size: 43px; font-weight: bold; line-height: 1em; margin: 0px; color: #6C3483"} to better capture effect modification over baseline covariates 
 - Check the model specification
 
\


## {}

![](Shin/paper.tiff){width="950" height="380" fig-align="center"}

<br>

::: {.callout-important}

## Aim

To predict the ATE of dabigatran vs warfarin on stroke/systemic embolism among patient with atrial Fibrillation in US Medicare beneficiaries 
:::

## [Identify the target population]{style="font-size: 67px; font-weight: light; line-height: 1em; margin: 0px; color: #6C3483 "}

<br>

![](Shin/diagram.tiff){width="1200" height="600" fig-align="center"}

::: {style="position: absolute; left: 380px; top: 800px; height: 50px; width: 150px; background-color: #ffffff; padding: 20px; padding-left: 10px; box-shadow: 0px 0px 10px 0px #4a235a; border-radius: 5px; border:0.2px solid #D9D9D9"}
[Trial population]{style="font-size: 20px; font-weight: bold; line-height: 0.5px; margin: 0px; color: #4a235a"}
:::

::: {style="position: absolute; left: 860px; top: 800px; height: 50px; width: 150px; background-color: #ffffff; padding: 20px; padding-left: 10px; box-shadow: 0px 0px 10px 0px #4a235a; border-radius: 5px; border:0.2px solid #D9D9D9"}
[$1^{st}$ Target pop.]{style="font-size: 20px; font-weight: bold; line-height: 0.5px; margin: 0px; color: #4a235a"}
:::

::: {style="position: absolute; left: 1200px; top: 800px; height: 50px; width: 150px; background-color: #ffffff; padding: 20px; padding-left: 10px; box-shadow: 0px 0px 10px 0px #4a235a; border-radius: 5px; border:0.2px solid #D9D9D9"}
[$2^{nd}$ Target pop.]{style="font-size: 20px; font-weight: bold; line-height: 0.5px; margin: 0px; color: #4a235a"}
:::


## Identify effect modifiers to be included in the model


<br>

![](Shin/EM.tiff){width="1200" height="600" fig-align="center"}

## Populations' characteristics

<br>

![](Shin/table2.tiff){width="1000" height="700" fig-align="center"}


## Prediction models^[equivalent to counterfactual probabilities of the outcomes had they been exposed to dabigatran or warfarin]

<br>

```{mermaid}
%%| fig-width: 15
%%{init: {'themeVariables': { 'primaryColor': '#ff0000',"fontSize": "15px"}}}%%
        graph LR
          A["Target population #32;" <br><br>.] --> B("Warfarin Model #32;")
          A["Trial population #32;"] --> C("Dabigatran Model #32;")
          C --> D["Risk Dabigatran #32;"]
          B --> E["Risk Warfarin #32;"]
          D --> F["RD or RR #32;"]
          E --> F["RD or RR #32;"]

```

## {}
![](Shin/table.tiff){width="1400" height="700" fig-align="center"}





## [Discussion]{style="font-size: 67px; font-weight: light; line-height: 1em; margin: 0px; color: #6C3483 "}

<br>

::: {.custom-callout}

[Populations had different distributions of some covariates and missing measured variables in target population]{style="font-size: 35px; font-weight: light; line-height: 1em; margin: 0px; color: #48494B "} 
 
:::

<br>

::: {.custom-callout}

[RR and RD for Stroke were similar between the target and trial population as __CHADS2 score__ strongly predicted Stroke]{style="font-size: 35px; font-weight: light; line-height: 1em; margin: 0px; color: #48494B "}

:::

<br>

::: {.custom-callout}

 [RWE (Observed) study might differ in how the outcome was ascertained and also the presence of confounding.]{style="font-size: 35px; font-weight: light; line-height: 1em; margin: 0px; color: #48494B "} [Does this enable us to compare it with the results from the prediction?]{style="font-size: 35px; font-weight: light; line-height: 1em; margin: 0px; color: #6C3483 "} 

:::

## Strength of outcome model-based prediction


::: {style="position: absolute; left: 140px; top: 200px; height: 400px; width: 480px; background-color: #ffffff; padding: 20px; padding-left: 50px; box-shadow: 0px 0px 10px 0px #fab724; border-radius: 5px; border:0.2px solid #D9D9D9"}

[Only one-time model development in a trial. The same model can be used in any target population that overlaps with the trial population.]{style="font-size: 43px; line-height: 1em; margin: 0px; color: #D69E02"}   

:::

::: {style="position: absolute; left: 800px; top: 200px; height: 400px; width: 480px; background-color: #ffffff; padding: 20px; padding-left: 50px; box-shadow: 0px 0px 10px 0px #fb92a4; border-radius: 5px; border:0.2px solid #D9D9D9"}

[The models are built from the trial data. Thus, confounding, differences in outcome ascertainment and follow-up are not an issue.]{style="font-size: 43px; line-height: 1em; margin: 0px; color: #B84C65"} [(typical challenges in observational studies)]{style="font-size: 30px; line-height: 1em; margin: 0px; color: #B84C65"}
:::



## Limitations

<br><br><br><br>

::: {style="position: absolute; left: 10px; top: 140px; height: 120px; width: 1400px; border:0px solid #D9D9D9 ;background-color: #ffffff; padding: 15px; padding-left: 20px; box-shadow: -5px 0px 0px 0px #6C3483; border-radius: 5px;"}
Avaibablitiy, distribution, and acertaintemnt of the covariates (for both trial and target population)
:::

 - [e.g., Leave out and relevant effect modifier that higly predict the outcome might understamate the predicted risk]{style="font-size: 30px; color: #808080"}
 
 <br><br><br><br><br>
 
::: {style="position: absolute; left: 10px; top: 500px; height: 120px; width: 1400px; border:0px solid #D9D9D9 ;background-color: #ffffff; padding: 15px; padding-left: 20px; box-shadow: -5px 0px 0px 0px #6C3483; border-radius: 5px;"}

 Those models cannot extrapolate estimates to target populations with characteristics explicitly excluded from the trial. 
:::
 - [e.g., RE-LY trial excluded individuals with heart valve disorders or active liver disease which might be associated with the increased risk of stroke or bleeding. Then, apply a developed model to no eligible trial participant model’s performance cannot be guaranteed]{style="font-size: 30px; color: #808080"}
 
 
## Advancing to personalised medicine {background-color="#471337"}

<br>

::: {.white-callout}

 [These methods enable us to generalise/transport ATE (ITE) from RCTs to clinical practice settings.]{style="font-size: 42px; color: #ffffff"}

:::

<br>

::: {.white-callout}

[They can be used in addition to observational studies, such as target trial emulation to estimate intervention benefit]{style="font-size: 42px; color: #ffffff"}

:::


<br>

::: {.white-callout}

[Outcome-based models show promise in predicting treatment effects in various target populations with different individual characteristics.]{style="font-size: 42px; color: #ffffff"}

:::

##  References

 - 	[Dahabreh IJ, Robertson SE, Steingrimsson JA, Stuart EA, Hernan MA. Extending inferences from a randomized trial to a new target population. Stat Med. 2020;39(14):1999-2014.]{style="font-size: 25px; line-height: 1em; margin: 0px"}
 
 - 	[Degtiar I, Rose S. A Review of Generalizability and Transportability. Annual Review of Statistics and Its Application. 2023;10(1):501-24.]{style="font-size: 25px; line-height: 1em; margin: 0px"}
 
 - 	[Robertson SE, Steingrimsson JA, Joyce NR, Stuart EA, Dahabreh IJ. Estimating subgroup effects in generalizability and transportability analyses. Am J Epidemiol. 2022.]{style="font-size: 25px; line-height: 1em; margin: 0px"}
 
 - 	[Dahabreh IJ, Robertson SE, Tchetgen EJ, Stuart EA, Hernán MA. Generalizing causal inferences from individuals in randomized trials to all trial-eligible individuals. Biometrics. 2019;75(2):685-94.]{style="font-size: 25px; line-height: 1em; margin: 0px"}
 
 - 	[Lesko CR, Buchanan AL, Westreich D, Edwards JK, Hudgens MG, Cole SR. Generalizing Study Results: A Potential Outcomes Perspective. Epidemiology. 2017;28(4):553-61.]{style="font-size: 25px; line-height: 1em; margin: 0px"}
 
 - 	[Ling AY, Montez-Rath ME, Carita P, Chandross KJ, Lucats L, Meng Z, et al. An Overview of Current Methods for Real-World Applications to Generalize or Transport Clinical Trial Findings to Target Populations of Interest. Epidemiology. 2023.]{style="font-size: 25px; ; line-height: 1em; margin: 0px"}
 
 - 	[Lee D, Yang S, Dong L, Wang X, Zeng D, Cai J. Improving trial generalizability using observational studies. Biometrics. 2023;79(2):1213-25.]{style="font-size: 25px; line-height: 1em; margin: 0px"}


##  {}

::: {style="position: absolute; left: 180px; top: 200px; height: 525px; width: 1200px; background-color: #ffffff; padding: 20px; padding-left: 50px; box-shadow: 0px 15px 0px 0px #6C3483; border-radius: 5px;"}
[Leveraging real-world data and randomised controlled trials to advance personalised medicine]{style="font-size: 70px; font-weight: bold; line-height: 1em; margin: 0px"}

<br>


[2023]{style="font-size: 50px;font-weight: bold;"}
:::


